AIBOTICS, INC. Annual Performance Review

I’ve put together this guide to help you understand Aibotics, Inc.’s performance this year. My goal is to explain their complex financial data in plain English so you can decide if this company fits your investment goals.

1. What does this company do?

Aibotics, Inc. (formerly Mycotopia Therapies) operates in two distinct fields:

• Psychedelic Research: They study mental health treatments, specifically using psilocybin to address depression and anxiety.
• Consumer Robotics: They develop hardware, including the "Phill Robot" (an AI-powered massage unit) and the "Milkyway" (a smart refrigerator for storing breast milk).

2. Strategic Direction

The company shifted its focus after acquiring assets from Philon Labs in the third quarter, moving toward an "AI-powered quality of life" model. Their current strategy is to use revenue from consumer hardware to fund the long-term development of their drug pipeline. By generating income through consumer tech, they aim to reduce their reliance on outside investors for daily operations.

3. Financial Health

The company is currently in a "survival and growth" phase. They reported a $4.2 million loss this year and maintain a cash runway of approximately nine months at their current spending rate. To fund the Philon Labs acquisition and robot manufacturing, they issued $2 million in preferred stock. Additionally, the board approved a plan to issue $7 million in stock options to employees over the next three years. For investors, this indicates that new shares will be issued, which may reduce your ownership percentage and the potential earnings per share.

4. Key Investment Risks

• Operational Focus: The company’s two divisions operate independently. The manufacturing of consumer appliances does not provide a direct advantage to the complex, highly regulated process of pharmaceutical drug testing.
• Regulatory Hurdles: The medical division is subject to the DEA’s classification of psilocybin. Because this research is in the early stages, any government delays in approvals or licensing could significantly impact the medical business.
• Dilution: With a market value of $18 million, the planned issuance of $7 million in new stock is substantial and could reduce existing ownership stakes by up to 38%.
• Operating Costs: The company spent $1.8 million on medical research and $1.5 million on the robotics launch. They must sell at least 5,000 "Milkyway" units annually to reach the break-even point for their hardware division.

5. Future Outlook

Aibotics maintains a lean cost structure by utilizing remote teams and third-party manufacturers. Their success hinges on two primary milestones: a successful holiday launch for the Phill Robot and securing a partner to help fund their ongoing drug trials. The company achieved a 12% profit margin on initial hardware sales, suggesting they are currently prioritizing market share over immediate profitability.

Investor Takeaway: This remains a high-risk, speculative investment. Until the company demonstrates consistent sales growth and secures external funding for their medical research, it is best to view this as a long-term play that requires close monitoring of their quarterly hardware sales and regulatory progress.